13 / 49
Conclusions
• With additional follow-up, dabrafenib + trametinib continued to show significant benefit over dabrafenib
monotherapy despite cross-over
– 3-year OS, 44% vs 32%
– 3-year PFS, 22% vs 12%
• Best 3-year outcome with dabrafenib + trametinib was observed in patients with normal LDH and < 3
disease sites
– 3-year OS, 62%
– 3-year PFS, 38%
• The safety profile was similar to previous reports for dabrafenib + trametinib, with no unexpected toxicities
• Longest OS follow-up among randomized phase 3 trials evaluating BRAFi + MEKi in patients
with
BRAF
-mutant metastatic melanoma
Presented by: Keith T. Flaherty, MD
NP4: 1606042435